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Available online xxxxAim: To investigate predictors of falls/fractures leading to hospitalisation in people with schizophrenia-spectrum
disorders.
Methods:A historical cohort of people with schizophrenia-spectrum disorders (ICD F20-29) from 01/2006–12/2012
was assembled using data from the South London and Maudsley NHS Biomedical Research Centre Case Register.
Falls/fractureswere ascertained from a linkage to national hospitalisation data. Separatemultivariate Cox regression
analyses were employed to identify predictors of falls and fractures.
Results:Of 11,567 peoplewith schizophrenia-spectrumdisorders (mean age 42.6 years, 43% female), 579 (incidence
rate 12.79 per 1000 person-years) and 528 (11.65 per 1000 person-years) had at least one reported hospital admis-
sion due to a fall or fracture respectively and 822 patients had at least either a recorded fall or a fracture during this
period (i.e. 7.1% of sample). Overall, 6.69 and 10.74 years of inpatient hospital stay per 1000-person years of follow-
up occurred due to a fall and fracture respectively. 14(0.12%) and 28(0.24%) died due to a fall and fracture respec-
tively. InMultivariable analysis, increasing age,white ethnicity, analgesics, cardiovascular disease, hypertension, dis-
eases of the genitourinary system, visual disturbance and syncope were signiﬁcant risk factor for both falls and
fractures. A previous fracture (HR 2.05, 95% CI 1.53–2.73) and osteoporosis (HR 6.79, 95% CI 4.71–9.78) were strong
risk factors for consequent fractures.
Conclusion: Comorbid physical health conditions and analgesicmedication prescriptionwere associatedwith higher
risk of falls and fractures. Osteoporosis and previous fracture were strong predictors for subsequent fractures. Inter-
ventions targeting bone health and falls/fractures need to be developed and evaluated in these populations.








Falls and fractures are associated with considerable morbidity, re-
duced quality of life and healthcare expenditure (Johnell & Kanis,
2004). In Europe, fractures account for more disability adjusted life
years (DALYs) than all common cancers, with the exception of lung can-
cer (Johnell & Kanis, 2006). Osteoporosis is a key risk factor that greatly
increases an individual's risk of experiencing a fracture (Kanis et al.,
2010, 2013). Fractures, particularly of the hip, are associated with sub-
stantial morbidity, healthcare costs, deterioration in mobility, reducedt, South London and Maudsley
dom.
. This is an open access article under
redictors of falls and fractur
Res. (2018), https://doi.org/1social function and admission to long term care facilities (Kanis,
2002a, 2002b, Johnell & Kanis, 2006, Kanis et al., 2010, 2013). Moreover,
reduced bone mineral density increases a person's risk of death from a
fall (Sanchez-Riera et al., 2014). In recognition of this, improving bone
health and preventing fractures are a global public health priority
(Kanis, 2002a, 2002b, Johnell & Kanis, 2006).
People with schizophrenia-spectrum disorders have a number of
risk factors which increase their risk of lower bone mineral density
and osteoporosis (Kishimoto et al., 2012), including high rates of diabe-
tes (Stubbs et al., 2015d), vitamin D deﬁciency (Lally et al., 2016), sed-
entary lifestyles (Stubbs et al., 2015b) and poor nutritional intake
(Dipasquale et al., 2013). Additionally, raised prolactin, which is associ-
ated with some antipsychotic agents, has been suggested to accelerate
bone loss (Tseng et al., 2015; De Hert et al., 2016; Gonzalez-Blancothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
es leading to hospitalization in people with schizophrenia spectrum
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2 B. Stubbs et al. / Schizophrenia Research xxx (2018) xxx–xxxet al., 2016). A recent meta-analysis found that people with
schizophrenia-spectrum disorders (with a mean age of 44 years) were
2.5 times more likely to have osteoporosis than controls (Stubbs et al.,
2014b). Another meta-analysis in this clinical population (with a
mean age of 33 years) concluded higher likelihood of reduced bone
mineral density (BMD) at the femur (standardised mean difference
(SMD) −0.5) and lumbar spine (SMD −1.23) compared to matched
controls without mental disorders (Gomez et al., 2016). Consistent
with this, another recent meta-analysis demonstrated that people
with schizophrenia are at a 72% increased risk of experiencing fractures
compared to the general population (Stubbs et al., 2015c). However, the
authors noted that there was a paucity of information on predictors of
fractures in people with schizophrenia-spectrum disorders, which
have only been investigated in three representative cohort studies to
date (Sorensen et al., 2013; Tsai et al., 2014; Wu et al., 2015). Of these,
one largely focussed on antipsychotic medication as an exposure (Wu
et al., 2015), two focussed only on hip fractures as an outcome
(Sorensen et al., 2013; Wu et al., 2015) and only one provided informa-
tion on predictors of fractures in Europe (Sorensen et al., 2013). No rep-
resentative cohort has, to the best of our knowledge, investigated the
predictors of falls in people with schizophrenia-spectrum disorders, de-
spite their importance as a precursor to fractures.
Given these limitations, we conducted a representative cohort study
investigating predictors of falls and fractures leading to hospitalisation
among people with schizophrenia-spectrum disorders (ICD 10 codes
F20-29). Secondarily, we investigated length of hospital stay as a result
of falls and fractures in this group.
2. Methods
2.1. Study setting and data source
A retrospective observational study was conducted using data from
the South London andMaudsley NHS Foundation Trust (SLaM) Biomed-
ical Research Centre (BRC) Case Register. SLaM is one of Europe's largest
mental healthcare providers, serving a geographic catchment of four
south London boroughs (Lambeth, Lewisham, Southwark, and Croydon)
with a population in excess of 1.2 million people. The data for the cur-
rent study were captured from the Clinical Record Interactive Search
(CRIS) application, which generates an anonymised version of SLaM's
electronic health record within a robust governance framework
(Perera et al., 2016a). The SLaM BRC Case Register has been described
in detail (Perera et al., 2016a) and has supported a range of studies
(Chang et al., 2010; Hayes et al., 2011; Perera et al., 2014; Sultana
et al., 2014; Ward et al., 2015; Perera et al., 2016b). Data are currently
archived in CRIS on over 350,000 cases with a range ofmental disorders
and the database, with associated data linkages, has approval for sec-
ondary analysis (Oxford Research Ethics Committee C, reference 08/
H0606/71 + 5). Data from CRIS have been supplemented through nat-
ural language processing (NLP) applicationsusingGeneralisedArchitec-
ture for Text Engineering (GATE) software, applying information
extraction techniques to derive structured information from the exten-
sive text ﬁelds held in the mental health record (Perera et al., 2016a).
2.2. Participants and study period
All SLaMpatientswith schizophrenia-spectrumdisorders, deﬁned as
schizophrenia, schizotypal and delusional disorder (ICD10 codes F20-
F29), with a diagnosis at any point between 1st of January 2007 and
31st March 2013, were included in the current study. SLaM patient re-
cords were linked with national Hospital Episode Statistics (HES)
which are compiled from all NHS Trusts in England (both acute and
mental health services), including statistical abstracts of records of all
inpatient episodes, as well as outpatient and emergency care (Perera
et al., 2016a). In addition CRIS datawere linked to the Ofﬁce for NationalPlease cite this article as: Stubbs, B., et al., Predictors of falls and fractur
disorder: A large representativ..., Schizophr. Res. (2018), https://doi.org/1Statistics (ONS) mortality records over the same period to investigate
mortality due to falls and fractures.
2.3. Primary outcome: falls and fractures
The primary outcomewas hospital admission resulting from a fall or
fracture extracted from linked HES data and all discharge diagnoses
(primary or any secondary diagnosis codes) recorded between January
2007 toMarch 2013 based on the following ICD 10 codes: i) falls (W00-
W19); ii) fractures (M80-M84, M907, S02, S12, S32, S42, S52, S62, S72,
S82, S92, S22, T02, T08, T10, T12X, T902, T911, T912, T921). In addition,
linked mortality records from the ONS were examined for any instance
of fall or fracture ICD codes in any cause of death ﬁeld on the death cer-
tiﬁcate to identify the date of death due to a fall or fracture.
2.4. Measurements
A range of additionalmeasurementswere obtained fromCRIS. All in-
dependent variables (covariates) were deﬁned according to the value
closest to the date of the ﬁrst recorded schizophrenia-spectrumdiagno-
sis. Demographic covariates comprised: age at diagnosis, gender, eth-
nicity (White-European and Non-White) and index of multiple
deprivation (IMD 2010) for the neighbourhood of residence (Lower
Super Output Area) at the time of diagnosis. The IMD has previously
been used in CRIS (Das-Munshi et al., 2017) and takes into account
area-level deprivation from Census data across several domains includ-
ing income, employment, health, education, barriers to housing and ser-
vices, living environment, and crime (Richardson et al., 2009).
Information on cohabiting status (Cohabiting: married/civil partner,
married, cohabiting; Non-cohabiting: single, divorced, civil partnership
dissolved, widowed, separated) was ascertained at the time of
schizophrenia-spectrum diagnosis, supplemented by a binary variable
derived using NLP on text mentions of the patient living alone.
The Health of the Nation Outcome Scales (HoNOS) (Wing et al.,
1998) are routinely administered measures of illness burden in UK
mental health services and are recorded in structured ﬁelds on the elec-
tronic health record. Individual HoNOS item scores (agitated behaviour,
self-injury, problem drinking & drugs, cognitive problems, physical ill-
ness, hallucinations, depressed mood, relationship problems, daily liv-
ing problems, living conditions problems, occupational problems) and
dates were obtained within 6 months before or after the index date
(date of schizophrenia-spectrum diagnosis), and the closest scores in
time to this date were included in analyses. Those scores 2 or over in
the Individual HoNOS scores were classiﬁed as having a problem on
each HoNOS score.
2.5. Mental disorder comorbidity
Diagnoses of affective disorders (ICD10 F30-F39), neurotic, stress-
related and somatoform disorders (F40-F48) were ascertained within
one year before or after the diagnosis of schizophrenia-spectrum.
2.6. Medication
Medications received by participants were extracted from struc-
tured medication ﬁelds in the record, supplemented by an NLP applica-
tions applied to text ﬁelds ascertaining mentions of current medication
(Perera et al., 2016a). Presence or not of the following medication
groups was ascertained on the basis of information within one year be-
fore or after ﬁrst diagnosis of schizophrenia-spectrumdisorders: benzo-
diazepines, anticholinergics, antihypertensives, antidepressants,
antipsychotics, anxiolytics and hypnotics, and analgesics. The total
number of medications prescribed was calculated for each participant
and used as a continuous variable.es leading to hospitalization in people with schizophrenia spectrum
0.1016/j.schres.2018.05.010
Table 1
Characteristics of those schizophrenia spectrum disorder patients whowere admitted to hospital with a fall/fracture after a diagnosis of schizophrenia spectrum disorders (F20* to F29*).
Characteristics of sample Presence of falls Presence of fractures
No (n= 10,988) Yes (n= 579) No (n= 11,174) Yes (n= 528)
Year of ﬁrst recorded diagnosis
2006 1826 (91.6) 167 (8.4) 1858 (93.2) 135 (6.8)
2007 2396 (93.9) 157 (6.1) 2399 (94) 154 (6)
2008 1573 (95.0) 83 (5.0) 1570 (94.8) 86 (5.2)
2009 1364 (96.1) 56 (3.9) 1360 (95.8) 60 (4.2)
2010 1403 (95.6) 64 (4.4) 1420 (96.8) 47 (3.2)
2011 1194 (96.8) 40 (3.2) 1204 (97.6) 30 (2.4)
2012 1232 (99.0) 12 (1.0) 1228 (98.7) 16 (1.3)
Age
18–34 4340 (98.0) 87 (2.0) 4319 (97.6) 108 (2.4)
35–49 3849 (97.6) 96 (2.4) 3822 (96.9) 123 (3.1)
50–64 1637 (92.8) 127 (7.2) 1655 (93.8) 109 (6.2)
65–79 892 (84.2) 167 (15.8) 943 (89.0) 116 (11.0)
80 & over 270 (72.6) 102 (27.4) 300 (80.6) 72 (19.4)
Gender
Female 4670 (93.9) 305 (6.1) 4711 (94.7) 264 (5.3)
Male 6318 (95.8) 274 (4.2) 6328 (96.0) 264 (4.0)
Ethnicity
White 5480 (92.7) 434 (7.3) 5529 (93.5) 385 (6.5)
Non-White 5508 (97.4) 145 (2.6) 5510 (97.5) 143 (2.5)
Marital status
Cohabiting 2356 (95.4) 113 (4.6) 2366 (95.8) 103 (4.2)
Non-cohabiting 8632 (94.9) 466 (5.1) 8673 (95.3) 425 (4.7)
Living status
Living with someone 8647 (95.6) 402 (4.4) 8678 (95.9) 371 (4.1)
Living alone 2341 (93.0) 177 (7.0) 2361 (93.8) 157 (6.2)
Index of multiple deprivation: IMD 2010 (SD) 29.4 (11.1) 29.3 (11.1) 29.5 (11.1) 28.9 (11.1)
Medication prescription (within one year before or after diagnosis schizophrenia spectrum disorders)
Benzodiazepines 3821 (95.9) 163 (4.1) 3831 (96.2) 153 (3.8)
Anticholinergics 5068 (95.8) 223 (4.2) 5079 (96.0) 212 (4.0)
Antihypertensive 1058 (88.5) 137 (11.5) 1095 (91.6) 100 (8.4)
Antidepressants 3161 (94.3) 192 (5.7) 3191 (95.2) 162 (4.8)
Antipsychotics 7714 (95.4) 371 (4.6) 7744 (95.8) 341 (4.2)
Anxiolytics and hypnotics 3753 (95.8) 166 (4.2) 3765 (96.1) 154 (3.9)
Analgesics 1130 (89.4) 134 (10.6) 1150 (91.0) 114 (9.0)
Number of medications received (within one year before or after diagnosis of schizophrenia spectrum disorder)
0 2198 (94.1) 138 (5.9) 2216 (94.9) 120 (5.1)
1 1733 (95.7) 78 (4.3) 1727 (95.4) 84 (4.6)
2 2163 (96.3) 82 (3.7) 2163 (96.3) 82 (3.7)
3 1476 (95.3) 73 (4.7) 1477 (95.4) 72 (4.6)
4 1800 (95.5) 85 (4.5) 1811 (96.1) 74 (3.9)
5 or more 1618 (92.9) 123 (7.1) 1645 (94.5) 96 (5.5)
Other psychiatric conditions (within one year before or after diagnosis schizophrenia spectrum disorders)
F40–F48 (neurotic, stress-related and somatoform disorders) 1178 (95.4) 57 (4.6) 1180 (95.5) 55 (4.5)
F30–F39 (mood [affective] disorders) 2920 (94.3) 177 (5.7) 2945 (95.1) 152 (4.9)
f30 & F31 (mania and bipolar disorders) 396 (94.1) 25 (5.9) 406 (96.4) 15 (3.6)
Problem HoNOS (score 2 or over) (within six months before or after diagnosis schizophrenia spectrum disorders)
Agitated behaviour 1917 (94.2) 118 (5.8) 1929 (94.8) 106 (5.2)
Self-injury 592 (94.3) 36 (5.7) 590 (93.9) 38 (6.1)
Problem drinking drugs 1329 (93.7) 89 (6.3) 1320 (93.1) 98 (6.9)
Cognitive problems 1715 (93.0) 130 (7.0) 1734 (94.0) 111 (6.0)
Physical illness 1856 (87.8) 259 (12.2) 1890 (89.4) 225 (10.6)
Hallucinations 4349 (94.9) 236 (5.1) 4362 (95.1) 223 (4.9)
Depressed mood 2587 (95.6) 120 (4.4) 2590 (95.7) 117 (4.3)
Relationship problems 3209 (94.9) 171 (5.1) 3220 (95.3) 160 (4.7)
Daily living problems 2593 (92.5) 210 (7.5) 2637 (94.1) 166 (5.9)
Living conditions problems score 1934 (94.9) 104 (5.1) 1953 (95.8) 85 (4.2)
Occupational problems 2747 (94.9) 147 (5.1) 2759 (95.3) 135 (4.7)
Mean overall HoNoS score (mean) 11.3 (9.4) 13.0 (10.8) 11.3 (9.5) 12.7 (8.9)
Number of missing HoNoS patients 2087 (96.3) 80 (3.7) 2083 (96.1) 84 (3.9)
Hospital admissions (within six months before or after diagnosis schizophrenia spectrum disorders)
Ischaemia + CHD + IHD 46 (37.4) 77 (62.6) 77 (62.6) 46 (37.4)
Arrhythmia + AF 56 (41.5) 79 (58.5) 75 (55.6) 60 (44.4)
Heart failure 7 (18.9) 30 (81.1) 28 (75.7) 9 (24.3)
Diabetes 68 (52.7) 61 (47.3) 84 (65.1) 45 (34.9)
Hypotension 13 (37.1) 22 (62.9) 20 (57.1) 15 (42.9)
(continued on next page)
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Table 1 (continued)
Characteristics of sample Presence of falls Presence of fractures
No (n= 10,988) Yes (n= 579) No (n= 11,174) Yes (n= 528)
Hypercholesterolemia 46 (46.5) 53 (53.5) 61 (61.6) 38 (38.4)
Hypertension 115 (45.3) 139 (54.7) 149 (58.7) 105 (41.3)
Diseases of genitourinary system including UTI 93 (49.7) 94 (50.3) 109 (58.3) 78 (41.7)
Osteoporosis 64 (68.1) 30 (31.9) 23 (24.5) 71 (75.5)
Visual disturbance and blindness 16 (53.3) 14 (46.7) 20 (66.7) 10 (33.3)
Hearing loss 12 (46.2) 14 (53.8) 14 (53.8) 12 (46.2)
Syncope or collapse 25 (34.7) 47 (65.3) 45 (62.5) 27 (37.5)
Parkinson's disease 43 (61.4) 27 (38.6) 53 (75.7) 17 (24.3)
Falls before diagnosis 414 (77.7) 119 (22.3) 434 (81.4) 99 (18.6)
Fractures before diagnosis 626 (84.4) 116 (15.6) 604 (81.4) 138 (18.6)
4 B. Stubbs et al. / Schizophrenia Research xxx (2018) xxx–xxx2.7. Physical comorbidity
Information on physical comorbidities were ascertained utilising the
data linkage between CRIS and national HES records. Information on all
ICD-10 diagnoses at discharge (primary or any secondary diagnosis
codes) for physical comorbidities was ascertained within 6 months be-
fore or after diagnosis of Schizophrenia spectrum disorders and the fol-
lowing binary variables generated: i) Ischaemia (I20, I21, I22)
+ coronary heart disease (CHD) (I25) + Ischaemic heart disease
(IHD); ii) Arrhythmia (I44-I49) + atrial ﬁbrillation (AF) (I48); iii)
Heart failure (I50); iv) Diabetes (E08, E09, E10, E11, E12, E13;
v) Hypotension (I95-99); vi) Hypercholesterolemia (E78); vii) Hyper-
tension (I10-15); viii) Diseases of genitourinary system including uri-
nary tract infections (UTI) (N39); ix) Osteoporosis (M80-85);
x) Visual Disturbance and Blindness (H53-54); xi) Hearing Loss (H90-
95); xii) Syncope or Collapse (R50-R69); xiii) Parkinson's Disease
(G20).
2.8. Statistical analysis
The study samplewas described initially in terms of demographic and
clinical variables, followedbyunadjustedCoxproportional hazardmodels
to predict the ﬁrst fall and ﬁrst fracture after schizophrenia-spectrum di-
agnosis separately. The predictor variables at baseline used in the ﬁrst
univariate models included sociodemographic information (year of
schizophrenia spectrum disorder diagnosis, mean age, gender, ethnicity,
marital status, living status), medications (benzodiazepines, antipsy-
chotics, anxiolytics & hypnotics, antidepressants, analgesics, anticholiner-
gics, antihypertensives), comorbid psychiatric diagnosis (F30-39 mood
disorders, F40-48 neurotic/stress disorders), HONOS scores (mean total
and each individual item) and physical health comorbidities (as indicated
above). Factors that were signiﬁcant (P b 0.05) in the univariate models
for fall and fracture outcomes were subsequently entered into the multi-
variable model. A ﬁnal multivariable Cox proportional hazards model,
using stepwise backward elimination technique where those variables
not signiﬁcant (P value b 0.05) were eliminated, with hazard ratios and
95% conﬁdence intervals (CI), was assembled removing all non-
signiﬁcant variables from the model. Correlation matrix of coefﬁcients of
coxmodelwas used investigate collinearity among independent variables
and found that number ofmedications received (polypharmacy)was sig-
niﬁcantly collinear with individual types of medication received and
therefore, polypharmacy variable was removed from ﬁnal predictors. All
analyses were conducted utilising STATA, version 13.
3. Results
The analysed cohort comprised 11,174 people with a schizophrenia-
spectrum disorder with a mean age of 42.6 years (SD: 16.70) of whom
with 43.01% patients were females. During the observation period,
822 of these patients had at least one hospital admission due to a fall
or fracture (7.1% of the sample) of whom 579 and 528 were admittedPlease cite this article as: Stubbs, B., et al., Predictors of falls and fractur
disorder: A large representativ..., Schizophr. Res. (2018), https://doi.org/1due to a fall and fracture respectively and 285 patients were admitted
to both falls and fractures in this cohort. The incidence rate of falls
among schizophrenia-spectrum disorder patients was 12.79 per 1000
person years. The incidence rate of fractures among the cohort was
11.65 per 1000 person years. Table 1 summarises characteristics of
thosewho had a fall or fracture compared to those who did not. Overall,
14 (0.12%) and 28 (0.24%) of patients died due to a fall and fracture re-
spectively based on their death certiﬁcate.
3.1. Length of hospital stay and mortality
Among the 822 who experienced a fall or fracture, the mean length
of hospital stay following a fall (n=579)was 10.83 days (range 0–216)
equating to a total of 6270 full days in hospital. The mean length of stay
in hospital following a fracture across the samplewas 20.20 days (range
0–222) and a total of 10,668 days. This equates to 12.83 years of inpa-
tient hospital stay for 1000-person years of follow-up due to a fall and
23.70 years of inpatient hospital stay for 1000-person years of follow-
up due to a fracture.
3.2. Factors associated with falls and fractures
Unadjusted predictors of fall/facture in Cox regression models are
summarised in Table 2.
3.3. Multivariate predictors of falls
Multivariate models of factors associated with falls are presented in
Table 3. In the ﬁnal model the following remained independent and sig-
niﬁcant factors associated with falls leading to hospilisation: older age
(HR per 10-year increment, Hazard ratio (HR) 1.49, 95% CI 1.40, 1.58),
non-cohabiting marital status (HR 1.34, 95% CI 1.05, 1.71), physical
health problems on the HONOS subscale (HR 1.48, 95% CI 1.21, 1.81),
and hospitalisations in which the following was recorded as either pri-
mary or one of the secondary discharge diagnoses: ischaemic heart dis-
ease (HR 1.72, 95% CI 1.26, 2.35), arrhythmia or atrial ﬁbrillation (HR
1.90, 95% CI 1.4, 2.59), diabetes (HR 1.78, 95%CI 1.27, 2.49), hypotension
(HR 1.78, 95% CI 1.1, 2.89), hypertension (HR 2.77, 95% CI 2.02, 3.8), dis-
eases of genitourinary system and UTI (HR 1.74, HR 95% CI 1.28, 2.36),
visual disturbance or blindness (HR 5.04, 95% CI 2.76, 9.19), syncope
(HR 2.12, 95% CI 1.46, 3.08), Parkinson's disease (HR 2.77, 95% CI 1.79,
4.27). Factors associated with a reduced risk of falls comprised non-
white ethnicity (HR0.50, 95% CI 0.4, 0.61) and antihypertensivemedica-
tion (HR 0.66, 95% CI 0.51, 0.87). There was no interaction between age
and gender with a P-value for Likelihood-ratio test of 0.962.
3.4. Multivariate predictors of fractures
Full details of themultivariate predictors of fractures are displayed in
Table 4. In the ﬁnal model, the following factors remained independent
and signiﬁcantly associated with hospitalisation due to fractures:es leading to hospitalization in people with schizophrenia spectrum
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5B. Stubbs et al. / Schizophrenia Research xxx (2018) xxx–xxxanalgesics (HR: 1.47, 95% CI 1.17, 1.86) and hospitalisations in the pri-
mary/secondary discharge diagnoses: hypertension (HR: 2.36, 95% CI
1.65, 3.38), diseases of the genitourinary system and UTIs (HR 1.83,
95% CI 1.29, 2.57), osteoporosis (HR: 6.79, 95% CI 4.71, 9.78), Arrhythmia
and atrialﬁbrillation (HR1.69, 95%CI 1.19, 2.39), Visual Disturbance and
Blindness (HR: 3.10, 95% CI 1.55, 6.21), and previous fracture before
psychosis (HR: 2.05, 95% CI 1.53, 2.73). Factors associated with a re-
duced risk of hospital admission due to fractures included Hypercholes-
terolemia (HR: 0.63, 95% CI 0.41, 0.96) and non-white ethnicity (HR
0.60, 95% CI 0.48, 0.74).Table 2
Univariate Cox proportional hazard model (95% CI) showing factors affecting time to ﬁrst fall/f
Characteristics Outcom
HR (95%








10-year increase in age 1.79 (1.
Female gender 1.5 (1.2
Non-white ethnicity 0.34 (0.
Non-cohabiting marital status 1.13 (0.
Living alone 1.61 (1.
Ten units increase in IMD score 0.98 (0.
Medication prescribed (within one year before or after diagnosis of schizophrenia spectrum di
Benzodiazepines received 0.82 (0.
Anticholinergics received 0.76 (0.
Antihypertensive received 2.86 (2.
Antidepressants received 1.21 (1.
Antipsychotics received 0.75 (0.
Anxiolytics and hypnotics received 0.85 (0.
Analgesics received 2.65 (2.
Increase in one type of polypharmacy 1.05 (1.
Presence of other psychiatric conditions (within one year before or after schizophrenia spectru
F40–F48 (neurotic, stress-related and somatoform disorders) present 0.88 (0.
F30–F39 (mood [affective] disorders) present 1.13 (0.
f30 & F31 (mania and bipolar disorders) 1.11 (0.
Problem HoNOS present (within 6 months before or after schizophrenia spectrum diagnosis)
Agitated behaviour 1.20 (0.
Self-injury 1.15 (0.
Problem drinking drugs 1.21 (0.
Cognitive problems 1.50 (1.
Physical illness 4.04 (3.
Hallucinations 1.00 (0.
Depressed mood 0.79 (0.
Relationship problems 0.92 (0.
Daily living problems 1.73 (1.
Living conditions problems 0.97 (0.
Occupational problems 0.95 (0.
Overall increase in one unit of HoNoS 1.02 (1.
Admitted to general hospital (within 6 months before or after schizophrenia spectrum diagno
Ischaemia + CHD + IHD 25.04 (1
Arrhythmia + AF 21.00 (1





Diseases of genitourinary system including UTI 22.41 (1
Osteoporosis 10.01 (6
Visual disturbance and blindness 18.82 (1
Hearing loss 26.12 (1
Syncope or collapse 23.16 (1
Parkinson's disease 13.68 (9
Falls before schizophrenia spectrum disorder diagnosis 7.06 (5.
Fractures before schizophrenia spectrum disorder diagnosis 4.19 (3.
Please cite this article as: Stubbs, B., et al., Predictors of falls and fractur
disorder: A large representativ..., Schizophr. Res. (2018), https://doi.org/14. Discussion
The study found that over a 6-year period, approximately 7.1% of
people receiving care for schizophrenia-spectrum disorders were ad-
mitted to an acute hospital setting due to a fall/fracture, equating to
an incidence rate 12.79 per falls 1000 person years and 11.65 fractures
per 1000 person years. Of concern, our data indicated that cohort mem-
bers who had a fall (n = 579) spent a total of 6270 days in hospital,
whilst those who had a fracture spent (n = 528) a total of
10,668 days in hospital. Multivariate models indicated increasing age,racture hospital admission since diagnosis of schizophrenia spectrum disorders.
e falls Outcome fractures
CI) P value HR (95% CI) P value
Ref.
65, 1.01) 0.059 1.04 (0.82, 1.32) 0.747
59, 1.01) 0.059 1.1 (0.83, 1.46) 0.519
55, 1.02) 0.070 1.1 (0.80, 1.51) 0.565
79, 1.45) 0.653 1.06 (0.75, 1.5) 0.747
87, 1.8) 0.236 1.19 (0.78, 1.8) 0.425
45, 1.53) 0.550 1.25 (0.72, 2.16) 0.423
72, 1.87) b0.001 1.54 (1.47, 1.61) b0.001
8, 1.77) b0.001 1.34 (1.13, 1.59) b0.001
28, 0.41) b0.001 0.38 (0.31, 0.46) b0.001
92, 1.39) 0.242 1.13 (0.91, 1.40) 0.277
35, 1.92) b0.001 1.55 (1.28, 1.86) b0.001
91, 1.06) 0.632 0.94 (0.87, 1.02) 0.152
sorders)
68, 0.98) 0.029 0.85 (0.71, 1.03) 0.099
64, 0.89) b0.001 0.81 (0.68, 0.96) 0.016
29, 3.57) b0.001 2.03 (1.57, 2.64) b0.001
02, 1.44) 0.027 1.08 (0.90, 1.3) 0.413
63, 0.89) 0.001 0.76 (0.64, 0.91) 0.003
71, 1.01) 0.069 0.87 (0.72, 1.05) 0.146
18, 3.21) b0.001 2.42 (1.97, 2.98) b0.001
00, 1.1) 0.037 1.03 (0.99, 1.08) 0.154
m diagnosis)
67, 1.15) 0.354 0.94 (0.71, 1.24) 0.655
94, 1.34) 0.192 1.03 (0.85, 1.24) 0.758
74, 1.66) 0.614 0.70 (0.42, 1.18) 0.180
98, 1.48) 0.077 1.22 (0.98, 1.52) 0.070
82, 1.61) 0.432 1.39 (1, 1.94) 0.051
96, 1.52) 0.110 1.59 (1.27, 1.99) b0.001
23, 1.84) b0.001 1.41 (1.14, 1.75) 0.002
39, 4.82) b0.001 3.79 (3.14, 4.56) b0.001
84, 1.2) 0.959 1.13 (0.94, 1.36) 0.191
65, 0.97) 0.026 0.90 (0.73, 1.11) 0.326
77, 1.11) 0.392 0.99 (0.82, 1.2) 0.919
45, 2.07) b0.001 1.38 (1.14, 1.67) 0.001
78, 1.2) 0.781 0.86 (0.68, 1.09) 0.219
78, 1.16) 0.623 1.00 (0.81, 1.22) 0.986
01, 1.02) b0.001 1.01 (1.01, 1.02) b0.001
sis)
9.63, 31.93) b0.001 12.35 (9.11, 16.73) b0.001
6.54, 26.66) b0.001 15.09 (11.52, 19.76) b0.001
7.62, 36.82) b0.001 6.31 (3.27, 12.21) b0.001
4.07, 24.02) b0.001 13.23 (9.73, 17.98) b0.001
6.43, 38.62) b0.001 14.81 (8.86, 24.78) b0.001
3.58, 23.95) b0.001 12.30 (8.84, 17.12) b0.001
0.46, 30.12) b0.001 17.13 (13.81, 21.26) b0.001
7.92, 28.03) b0.001 18.55 (14.55, 23.64) b0.001
.93, 14.47) b0.001 54.27 (42.04, 70.07) b0.001
1.06, 32.02) b0.001 11.01 (5.89, 20.6) b0.001
5.33, 44.49) b0.001 17.97 (10.12, 31.89) b0.001
7.16, 31.25) b0.001 11.92 (8.09, 17.57) b0.001
.29, 20.16) b0.001 7.92 (4.88, 12.85) b0.001
77, 8.64) b0.001 6.17 (4.95, 7.68) b0.001
42, 5.14) b0.001 6.12 (5.04, 7.44) b0.001
es leading to hospitalization in people with schizophrenia spectrum
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Table 3
Two models showing predictors of ﬁrst fall hospital admission among schizophrenia spectrum disorders (used stepwise removal of factors that were not signiﬁcant at 0.05 P value).
Characteristics Model 1 (n= 9236) Model 2 (n= 9366)
HR (95% CI) P value HR (95% CI) P value
10-year increase in age 1.50 (1.40, 1.60) b0.001 1.49 (1.40, 1.58) b0.001
Female gender 0.97 (0.80, 1.18) 0.797
Non-white ethnicity 0.48 (0.39, 0.60) b0.001 0.50 (0.4, 0.61) b0.001
Non-cohabiting marital status 1.29 (1.00, 1.66) 0.05 1.34 (1.05, 1.71) 0.025
Living alone 1.10 (0.90, 1.35) 0.355
Medication prescribed (within one year before or after diagnosis of schizophrenia spectrum disorder)
Anticholinergics received 1.21 (0.98, 1.50) 0.078
Antihypertensive received 0.61 (0.46, 0.81) b0.001 0.66 (0.51, 0.87) 0.026
Antidepressants received 1.12 (0.91, 1.37) 0.289
Antipsychotics received 0.79 (0.63, 0.99) 0.043 0.88 (0.73, 1.07) 0.183
Analgesics received 1.43 (01.14, 1.80) 0.002 1.48 (1.19, 1.85) 0.001
Problem HoNOS present (within 6 months before or after schizophrenia spectrum diagnosis)
Cognitive problems 1.23 (0.98, 1.53) 0.073
Physical illness 1.44 (1.17, 1.78) b0.001 1.48 (1.21, 1.81) b0.001
Depressed mood 0.91 (0.73, 1.14) 0.415
Daily living problems 0.95 (0.77, 1.17) 0.645
Admitted to general hospital (within one year before or after diagnosis of schizophrenia spectrum disorder)
Ischaemia + CHD + IHD 1.80 (1.28, 2.55) b0.001 1.72 (1.26, 2.35) b0.001
Arrhythmia + AF 1.91 (1.39, 2.63) b0.001 1.90 (1.4, 2.59) b0.001
Heart failure 1.29 (0.79, 2.08) 0.307
Diabetes 1.77 (1.24, 2.51) b0.001 1.78 (1.27, 2.49) b0.001
Hypotension 1.92 (1.17, 3.14) 0.010 1.78 (1.1, 2.89) 0.007
Hypercholesterolemia 0.88 (0.60, 1.28) 0.508
Hypertension 2.79 (1.98, 3.95) b0.001 2.77 (2.02, 3.8) b0.001
Diseases of genitourinary system including UTI 1.79 (1.30, 2.47) b0.001 1.74 (1.28, 2.36) b0.001
Osteoporosis 1.05 (0.68, 1.62) 0.820
Visual disturbance and blindness 5.01 (2.66, 9.43) b0.001 5.04 (2.76, 9.19) b0.001
Hearing loss 1.25 (0.70, 2.23) 0.459
Syncope or collapse 2.01 (1.37, 2.96) b0.001 2.12 (1.46, 3.08) b0.001
Parkinson's disease 2.71 (1.72, 4.26) b0.001 2.77 (1.79, 4.27) b0.001
Falls before schizophrenia spectrum disorder diagnosis 0.85 (0.62, 1.16) 0.306
Fractures before schizophrenia spectrum disorder diagnosis 1.10 (0.82, 1.50) 0.515
Model 1 includes all signiﬁcant univariable predictors of falls, whilst model 2 is the ﬁnal model and includes only signiﬁcant predictors of falls after removal of non-signiﬁcant (at P b 0.05
level) predictors.
6 B. Stubbs et al. / Schizophrenia Research xxx (2018) xxx–xxxa history of co-morbid physical illnesses (in particular cardiovascular
and metabolic diseases), analgesic use were associated with an in-
creased hazard of hospital admission due to falls and fractures, whilst
receipt of antihypertensive medication, and being non-white ethnicity
were all associated with a reduced risk. We found no relationship be-
tween antipsychotic medication and falls or fractures in the fully ad-
justed models. Of note, a previous fracture and osteoporosis were
strong risk factors for future fractures in the cohort, which is a concern
given that a previous meta-analysis found that half of people with
schizophrenia-spectrum disorders had osteoporosis or osteopenia
(Stubbs et al., 2014b). Given that the falls recorded were those that re-
quired hospitalisation (i.e. themost severe), the true incidence of actual
falls is likely to be much higher.
Our data shed new light on the hospital length of stay burden from
people with schizophrenia who experience a fall of fracture. The rate
of inpatient hospital stay of 12.79 and 11.65 years per 1000-person
years of follow-up due to a fall and fracture respectively is of concern.
Little previous information is available on the length and duration of
hospital admission due to falls and fractures in schizophrenia spectrum
disorders. A previous study considering over 10 million hip fractures in
a range of psychiatric conditions (Menendez et al., 2013), established
that patients with schizophrenia (0.6% of the sample) spent more time
in hospital than (11 days) than any other patient group, including
those with dementia, where there has been an increasing body of re-
search attempting to prevent falls and fractures (Bunn et al., 2014;
Chan et al., 2015). The authors (Menendez et al., 2013) found that
lengthened stay was attributed to the greatly increased number of ad-
verse events such as pneumonia, acute renal failure and deep venous
thrombosis compared to those without mental illness.Please cite this article as: Stubbs, B., et al., Predictors of falls and fractur
disorder: A large representativ..., Schizophr. Res. (2018), https://doi.org/1There is considerable recognition from the generalmedical literature
that the development and prediction of fractures is complex and multi-
factorial (Kanis, 2002a, 2002b; Kanis et al., 2010, 2013). The risk factors
for falls and fractures in people with schizophrenia-spectrum disorders
are perhaps evenmore complex/multifactorial and our data attempts to
disentangle some of the key risk factors. Speciﬁcally, our data suggest
that pre-existing comorbid physical health conditions, particularly car-
diovascular, metabolic and osteoporosis are associated with future hos-
pital admissions due to falls. An extensive evidence base has
demonstrated that people with schizophrenia-spectrum have consider-
ablyworse physical health compared to the general population (DeHert
et al., 2011a, 2011b; Correll et al., 2015) including diabetes and cardio-
metabolic abnormalities (Vancampfort et al., 2015, 2016; Correll et al.,
2017) which are known to be key risk factors for fractures
(Abdulameer et al., 2012). Despite the poor physical health of people
with schizophrenia spectrum, few studies have considered comorbid
physical illnesses and falls. To our knowledge, only one study (Tsai
et al., 2014) has previously established that diabetes (HR 1.55) and hy-
pertension (HR 1.24) were associated with hip fractures in people with
schizophrenia. Our data suggest that arrhythmia and atrial ﬁbrillation,
hypertension, genitourinary disease and UTIs, visual disturbance and
blindness, and syncope or collapse are associated with an increased
longer-term risk of both falls and fractureswhilst diabetes, hypotension,
Parkinson's disease were associated with falls only. Osteoporosis was a
signiﬁcant risk factor for fractures only. It should clearly be noted that
these diagnoses were extracted from those associated with previous
hospitalisations (although not necessarily the primary cause of the
hospitalisation), andwill represent an underestimation. Perhaps unsur-
prisingly, osteoporosis, a common condition in schizophrenia at a muches leading to hospitalization in people with schizophrenia spectrum
0.1016/j.schres.2018.05.010
Table 4
Two models showing predictors of ﬁrst fracture hospital admission among schizophrenia spectrum disorder patients.
Characteristics Model 1 (n= 9176) Model 2 (n= 9203)
HR (95% CI) P value HR (95% CI) P value
10-year increase in age 1.27 (1.19, 1.36) b0.001 1.27 (1.19, 1.35) b0.001
Female gender 0.97 (0.79, 1.2) 0.776
Non-white ethnicity 0.60 (0.48, 0.75) b0.001 0.60 (0.48, 0.74) b0.001
Living alone 1.17 (0.95, 1.44) 0.147
Medication prescribed (within one year before or after diagnosis of schizophrenia spectrum disorder)
Anticholinergics received 1.03 (0.82, 1.28) 0.817
Antihypertensive received 0.79 (0.58, 1.09) 0.156
Antipsychotics received 0.91 (0.72, 1.16) 0.456
Analgesics received 1.51 (1.18, 1.93) b0.001 1.47 (1.17, 1.86) b0.001
Problem HoNOS present (within 6 months before or after schizophrenia spectrum diagnosis)
Self-injury 1.16 (0.8, 1.67) 0.432
Problem drinking drugs 2.00 (1.56, 2.58) b0.001 2.17 (1.7, 2.77) b0.001
Cognitive problems 1.16 (0.91, 1.46) 0.224
Physical illness 1.72 (1.38, 2.15) b0.001 1.72 (1.38, 2.15) b0.001
Daily living problems 0.72 (0.58, 0.9) 0.004 0.77 (0.62, 0.94) 0.013
Admitted to general hospital (within one year before or after diagnosis of schizophrenia spectrum disorder)
Ischaemia + CHD + IHD 1.31 (0.88, 1.95) 0.186
Arrhythmia + AF 1.67 (1.16, 2.41) 0.005 1.69 (1.19, 2.39) 0.003
Heart failure 0.56 (0.27, 1.17) 0.124
Diabetes 1.54 (1.03, 2.32) 0.036 1.37 (0.92, 2.05) 0.117
Hypotension 1.34 (0.75, 2.38) 0.321
Hypercholesterolemia 0.59 (0.38, 0.92) 0.021 0.63 (0.41, 0.96) 0.031
Hypertension 2.38 (1.64, 3.45) b0.001 2.36 (1.65, 3.38) b0.001
Diseases of genitourinary system including UTI 1.93 (1.36, 2.75) b0.001 1.83 (1.29, 2.57) b0.001
Osteoporosis 6.92 (4.76, 10.06) b0.001 6.79 (4.71, 9.78) b0.001
Visual disturbance and blindness 3.13 (1.53, 6.43) 0.002 3.10 (1.55, 6.21) b0.001
Hearing loss 1.62 (0.86, 3.07) 0.136
Syncope or collapse 2.25 (1.39, 3.63) 0.001 2.30 (1.45, 3.67) b0.001
Parkinson's disease 1.20 (0.67, 2.16) 0.538
Falls before schizophrenia spectrum disorder diagnosis 0.69 (0.49, 0.97) 0.034 0.80 (0.58, 1.1) 0.164
Fractures before schizophrenia spectrum disorder diagnosis 1.96 (1.46, 2.64) b0.001 2.05 (1.53, 2.73) b0.001
Model 1 includes all signiﬁcant univariable predictors of fractures, whilst model 2 is the ﬁnal model and includes only signiﬁcant predictors of fractures after removal of non-signiﬁcant
(at P b 0.05 level) predictors.
7B. Stubbs et al. / Schizophrenia Research xxx (2018) xxx–xxxyounger age than the general population (Stubbs et al., 2014b), was
strongly (HR: 6.79) associated with hospital admission due to fractures.
Moreover, a previous fracturewas also associatedwith a future fracture.
Despite this, there are, to the best of our knowledge, no interventions
that have speciﬁcally sought to prevent ormanage osteoporosis or frac-
tures in peoplewith schizophrenia-spectrumdisorders. This is a point of
major inequity, especially given that a recent meta-analysis demon-
strated that 50% of people with schizophrenia spectrum with a mean
age of 44 years had low bone mass (i.e. osteopenia or osteoporosis) ac-
cording to DEXA scans (Stubbs et al., 2014c).
Interestingly, we found no relationship between antipsychotic med-
ication and falls or fractures in the full adjustedmodels. The literature to
date considering the impact of antipsychotic medication on both bone
mineral density and fractures has lacked clarity and has been
compounded by failure to consider other important confounders
(De Hert et al., 2016). A previous review (Kishimoto et al., 2012)
found that whilst 60% of studies suggested that antipsychotic medica-
tion, and in particular prolactin-raising medication, was associated
with lower bone mineral density, there were inadequacies in the con-
sideration of other risk factors and the studies were hampered by
small sample sizes. When considering fractures, some studies have not
found that antipsychotic medication is associated with fractures
(Bolton et al., 2008) whilst other studies have (Sorensen et al., 2013;
Tsai et al., 2014; Wu et al., 2015). A recent study in Canada found that
antipsychotic medication (across several psychiatric diagnoses) was
an independent predictor of hip fracture above and beyond traditional
risk factors considered in the FRAX fracture risk assessment tool
(Bolton et al., 2017). The reasons for the inconsistencies are not clear
but warrent further investigation. Also of surprise is that in the univar-
iate analysis benzodiapines were not associated with falls and the pre-
cise reasons for this are unclear. In addition, the univariable modelsPlease cite this article as: Stubbs, B., et al., Predictors of falls and fractur
disorder: A large representativ..., Schizophr. Res. (2018), https://doi.org/1suggested that anticholinergic medication appeared protective of falls,
although this disappeared in the multivariable models, suggesting
other factors highlighted above are more important. Our data also sug-
gests that analgesics agents may be associated with falls and fractures.
In the general population, research has demonstrated that analgesic
use (Leveille et al., 2002) and pain (Stubbs et al., 2014a) are associated
with falls. A previousmeta-analysis demonstrated that a third of people
with schizophrenia spectrum had clinical pain (Stubbs et al. (2014d)).
The underlying relationship between analgesics and increased falls,
may in fact be attributed to underlying physical comorbidities, although
clearly more work is required to understand these relationships. How-
ever, our data was also suggest that antihypertensive medication was
associated with reduced falls but not fractures. Finally, non-white eth-
nicity was associated with a protective effect of falls and fractures in
the sample. The reasons for this are unclear and warrant investigation.
The current study adds to the limited data on hospital admission due
to falls, which are often a precursor to fractures. A number of physical
comorbidities recorded were associated with both falls and fractures,
which is in line with the general falls/fracture literature. Much in line
with the absence of efforts to improve the bone health and prevent frac-
tures in people with schizophrenia spectrum, there is to the best of our
knowledge no interventions that have sought to understand or prevent
falls in this population. Given the remarkably poor bone health at young
age (50% with low bone mass at 44 years) (Stubbs et al., 2014b), in-
creased fracture and falls risk and the increased adverse consequences
which appear more marked than other at risk populations (Menendez
et al., 2013), the absence of research attempting to improve bone health
and prevent falls and fractures strikes as a major inequity.
Our data have potentially important implications for clinicians and
policy makers. The key message is that people with schizophrenia-
spectrum disorders should be screened for falls risk, particularly thosees leading to hospitalization in people with schizophrenia spectrum
0.1016/j.schres.2018.05.010
8 B. Stubbs et al. / Schizophrenia Research xxx (2018) xxx–xxxwho are older, or who have comorbid medical comorbidities (particu-
larly cardiovascular disease). In addition to screening for traditional
falls risk factors such as the assessment of gait, balance and mobility,
muscle weakness and visual impairments, such an assessment should
also include an evaluation of the risk for osteoporosis, a cardiovascular
and metabolic examination, a medication review in order to identify
people at high risk. Given the reduced bonemineral density amongpeo-
ple with schizophrenia-spectrum (De Hert et al., 2016) it is imperative
that any falls screening interventions seek to also target improvements
in bone health. If a person is identiﬁed as being a high risk of falls, mul-
tifactorial interventions should include an exercise component under
supervision of a physiotherapist, given that exercise was identiﬁed as
the most consistently effective intervention to prevent falls in older
adults (Stubbs et al., 2015a), although clearly research speciﬁcally
among people with schizophrenia-spectrum is required to establish
the best evidence.
Whilst the current data are novel, some important limitations
should be noted. First, it was not possible to collect information on
pre-fall/fracture mobility, balance and physical performance levels,
which are key risk factors for falls (Deandrea et al., 2010). Additional re-
search is required to understand mobility limitations for people with
psychosis and speciﬁcally if interventions can be developed to reduce
these pertinent risk factors. Second, it was not possible to decipher the
different types of fracture that occurred during the study. Future re-
search is required to explore this,with a particular emphasis on hip frac-
tures which are associated with particular deleterious outcomes
(Menendez et al., 2013). Third, the study relied only on falls and frac-
tures leading a hospital admission, thus it is likely that the ﬁgures and
predictors for falls in particular may differ and require investigation.
Fourth, it was not possible to decipher the potential differential effects
of individual antipsychotic agents and their relationship with falls and
fractures. Fifth, schizophrenia spectrum is recognised as beingheteroge-
neous and future research should consider how the risk and predictors
of falls and fractures may differ on this diagnostic continuum. Finally,
we did not have a healthy control group to compare the outcomes and
predictors of the study.
5. Conclusion
Our data found that over a 6 year period, 7% of a large cohort
with schizophrenia spectrum were admitted to hospital due to a fall
or fracture. Much in line with the general population, older age, comor-
bid physical health disorders and some physical health medications are
predictors of falls and fractures in people with schizophrenia spectrum
disorders. Of note, osteoporosis and a previous fracture were strongly
associated with a subsequent fracture. The mean and total length of
stay following falls and fractures for people with schizophrenia-
spectrum are considerable. Our study investigated falls requiring
hospitilisation (i.e. the most severe end of the spectrum) and falls of a
less severe nature are almost certainly more common and future re-
search is required to understand this issue. Future bone health promo-
tion interventions targeting reducing falls and fractures are indicated
among people with schizophrenia spectrum.
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